Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Insurance companies can no longer implement harmful co-pay accumulator policies.
In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.
Stop me if you’ve heard this one before.
If the price is lowered with a generic version of PrEP, activists say, “we could end the HIV epidemic without a vaccine.”
Older drugs, many on the market for years, are rising in cost much faster than inflation.
A new study examines the clinical and economic impact of new direct-acting antivirals.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
The FDA commissioner wants drugmakers to “end the shenanigans.”
He’ll oversee the FDA, Medicare and Medicaid at a time when soaring drug prices remain a contentious political topic.
U.S. lawmakers say appointing Azar is like putting “the pharmaceutical fox in charge of the health care henhouse.”
Last week, the president announced that biosimilar drugs would no longer get special incentives on state Medicaid markets.
Outlined in a Health Affairs Blog post, the recommendations come from the Treatment Action Group and the Fair Pricing Coalition.
Tom Price now faces a Senate confirmation hearing.
Jim O’Neill is also interested in immortality. For real.
Report by HIV and hepatitis C advocates gives lawmakers and the White House a 100-day road map to tackling drug costs.
Confusion over drug prices, insurance and copays can cost both patients and providers thousands of dollars in unnecessary expenses.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.